

**School of Biomedical Science****Master of Science in Medical Biotechnology  
Semester End Examination - Jun 2024****Duration : 180 Minutes  
Max Marks : 100****Sem II - Q1PP205T - MBAMBT2007 - Pharmacogenomics**General Instructions*Answer to the specific question asked**Draw neat, labelled diagrams wherever necessary**Approved data hand books are allowed subject to verification by the Invigilator*

- |     |   |        |
|-----|---|--------|
| 1)  | Define the Downregulation of gene   | K1(2)  |
| 2)  | Explain the pro-drug pharmacogenomics   | K2(4)  |
| 3)  | Explain, how pharmacogenomics can help in disease risk stratification   | K2(6)  |
| 4)  | Illustrate the applications of DNA Biochip  | K3(9)  |
| 5)  | Illustrate the New Paradigm Shift in Treatment due to PM  | K3(9)  |
| 6)  | Examine the steps for DNA Sequencing and correlate its application with personalized medicine.  | K5(10) |
| 7)  | Analyze the pattern of reactions of Active Drug and Pro-drug for poor metabolizer, intermediate metabolizer, extensive metabolizer and ultrarapid metabolizer | K4(12) |
| 8)  | Examine the Single Nucleotide Polymorphism (SNP). Discuss its importance in varied Drug Response.   | K5(15) |
| 9)  | Examine the mechanism of Uridine diphosphate glucuronosyltransferases (UGTs) and Sulfotransferases (SULTs)  | K5(15) |
| 10) | Discuss the Pharmacogenomics of cardiovascular system   | K6(18) |